Cerus Corp (CERS, Financial) CFO Kevin Green sold 82,657 shares of the company on September 4, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $2.16 per share, totaling approximately $178,539. The insider now owns 536,093 shares of Cerus Corp.
Cerus Corp is engaged in the development and commercialization of the INTERCEPT Blood System to enhance blood safety. The system is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites that may be present in donated blood. The INTERCEPT Blood System is marketed globally to blood centers, hospitals, and other healthcare institutions.
Over the past year, Kevin Green has sold a total of 125,212 shares of Cerus Corp and has not made any purchases of the stock. The insider transaction history for Cerus Corp shows a pattern of more insider sales than buys over the past year, with 11 insider sells and 5 insider buys.
Shares of Cerus Corp were trading at $2.16 on the day of the sale, giving the company a market cap of approximately $385.418 million. According to the GF Value, the stock has a price-to-GF-Value ratio of 0.69, suggesting that it is a Possible Value Trap, Think Twice.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sell event may be of interest to investors tracking insider behaviors and evaluating the potential impact on Cerus Corp's stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
